{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:08:09Z","timestamp":1794856089108,"version":"4.9.1"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The management of advanced epithelial ovarian cancer (AOC) has undergone significant advancements with the emergence of molecular diagnostics, particularly in predicting responses to PARP inhibitors (PARPi) based on homologous recombination deficiency (HRD) status. However, understanding sensitivity and resistance beyond HRD status remains elusive. This study aims to explore molecular factors that may elucidate why HRD status does not consistently predict PARPi sensitivity. Therefore, we conducted a post hoc translational analysis of formalin-fixed paraffin-embedded tumor samples from the ENGOT-ov24\/NSGO-AVANOVA part 1 and 2 trial (NCT02354131), focusing on alterations pertaining radiologic response and progression-free survival (PFS). DNA sequencing was performed using the TruSight Oncology 500 HT gene panel, with variants classified according to recent guidelines. HRD status had been assessed by Myriad MyChoice CDx. We identified, among 92 patients in the ENGOT-ov24\/NSGO-AVANOVA part 1 and 2 trial, 151 pathogenic or likely pathogenic variants across 81 samples. PARPi-sensitizing variants were found in two out of 10 HRD-negative samples from patients with clinical benefit (PFS \u226512 months), whereas three out of 10 HRD-positive samples from patients having no benefit (PFS \u22646 months) harbored variants associated with PARPi resistance. Additionally, analysis of BRCA1 variants revealed that truncating variants in exon 11 correlated with clinical benefit when niraparib was combined with bevacizumab. Conclusively, our findings highlight the complexity of PARPi response in AOC and underscore the importance of exploring somatic variants beyond HRD status. Further investigation into exon 11 variants of BRCA1 and the potential of combination treatment is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0294","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T13:21:34Z","timestamp":1732627294000},"page":"3190-3200","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5787-5412","authenticated-orcid":false,"given":"Maj K.","family":"Kjeldsen","sequence":"first","affiliation":[{"name":"1Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark."},{"name":"2Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark."},{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0100-9060","authenticated-orcid":false,"given":"Morten","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5563-8197","authenticated-orcid":false,"given":"Dina Sofie B.","family":"Gr\u00f8nseth","sequence":"additional","affiliation":[{"name":"2Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-509X","authenticated-orcid":false,"given":"Martin","family":"Sch\u00f8nemann-Lund","sequence":"additional","affiliation":[{"name":"4Department of Anesthesia and Intensive Care, Odense University Hospital, Odense, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-3497","authenticated-orcid":false,"given":"Gitte-Bettina","family":"Nyvang","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"5Department of Oncology, Odense University Hospital, Odense, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6571-2196","authenticated-orcid":false,"given":"Charlotte Aaquist","family":"Haslund","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"6Department of Oncology, Aalborg University Hospital, Aalborg, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1871-3087","authenticated-orcid":false,"given":"Anja Oer","family":"Knudsen","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"5Department of Oncology, Odense University Hospital, Odense, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9176-5599","authenticated-orcid":false,"given":"Anne Krejbjerg","family":"Motavaf","sequence":"additional","affiliation":[{"name":"6Department of Oncology, Aalborg University Hospital, Aalborg, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4059-1349","authenticated-orcid":false,"given":"Susanne","family":"Malander","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"7Department of Oncology, Skane University Hospital, Lund University, Lund, Sweden."},{"name":"8Department of Clinical Science, Skane University Hospital, Lund University, Lund, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6347-4180","authenticated-orcid":false,"given":"Maarit","family":"Anttila","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"9Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9494-1765","authenticated-orcid":false,"given":"Gabriel","family":"Lindahl","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"10Department of Oncology, Link\u00f6ping University, Link\u00f6ping, Sweden."},{"name":"11Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-6912","authenticated-orcid":false,"given":"Johanna","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"12Tampere University and Cancer Center, Tampere University Hospital, Tampere, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6967-164X","authenticated-orcid":false,"given":"Maria","family":"Dimoula","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"13Department of Oncology, Uppsala University Hospital, Uppsala, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3868-7795","authenticated-orcid":false,"given":"Theresa L.","family":"Werner","sequence":"additional","affiliation":[{"name":"14Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1171-0971","authenticated-orcid":false,"given":"Trine Zeeberg","family":"Iversen","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"15Department of Oncology, Herlev-Gentofte University Hospital, Herlev, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4734-4743","authenticated-orcid":false,"given":"Sakari","family":"Hietanen","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"16Department of Obstetrics and Gynecology, Turku University Hospital and FICAN West, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4382-4694","authenticated-orcid":false,"given":"Lars","family":"Fokdal","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"17Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Odense, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6166-3532","authenticated-orcid":false,"given":"Hanna","family":"Dahlstrand","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"18Department of Oncology-Pathology, Karolinska Institutet and Theme Cancer, Karolinska University Hospital, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-2770","authenticated-orcid":false,"given":"Line","family":"Bj\u00f8rge","sequence":"additional","affiliation":[{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."},{"name":"19Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway."},{"name":"20Department of Clinical Science, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-4225","authenticated-orcid":false,"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[{"name":"21Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-1010","authenticated-orcid":false,"given":"Mansoor R.","family":"Mirza","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark."},{"name":"3Nordic Society of Gynecological Oncology-Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4325-3027","authenticated-orcid":false,"given":"Maria","family":"Rossing","sequence":"additional","affiliation":[{"name":"2Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark."},{"name":"22Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"2025051308430031600_bib1","doi-asserted-by":"crossref","first-page":"e2200555","DOI":"10.1200\/PO.22.00555","article-title":"Normalized LST is an efficient biomarker for homologous recombination deficiency and olaparib response in ovarian carcinoma","volume":"7","author":"Christinat","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2025051308430031600_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejca.2023.04.020","article-title":"PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1\/ENGOT-ov25 trial","volume":"188","author":"Loverix","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025051308430031600_bib3","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.3390\/cancers15133445","article-title":"Development of the NOGGO GIS v1 assay, a comprehensive hybrid-capture-based NGS assay for therapeutic stratification of homologous repair deficiency driven tumors and clinical validation","volume":"15","author":"Willing","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025051308430031600_bib4","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41388-023-02839-8","article-title":"Shallow whole genome sequencing approach to detect homologous recombination deficiency in the PAOLA-1\/ENGOT-OV25 phase-III trial","volume":"42","author":"Callens","year":"2023","journal-title":"Oncogene"},{"key":"2025051308430031600_bib5","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1158\/1078-0432.CCR-23-0898","article-title":"Validation of the clinical use of GIScar, an academic-developed genomic instability score predicting sensitivity to maintenance olaparib for ovarian cancer","volume":"29","author":"Leman","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025051308430031600_bib6","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"2025051308430031600_bib7","doi-asserted-by":"crossref","first-page":"e2300483","DOI":"10.1200\/PO.23.00483","article-title":"Combining homologous recombination-deficient testing and functional RAD51 analysis enhances the prediction of poly (ADP-Ribose) polymerase inhibitor sensitivity","volume":"8","author":"Korsholm","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2025051308430031600_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"2025051308430031600_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neo.2014.04.003","article-title":"VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2","volume":"16","author":"Lim","year":"2014","journal-title":"Neoplasia"},{"key":"2025051308430031600_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann Oncol"},{"key":"2025051308430031600_bib11","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","article-title":"Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial","volume":"20","author":"Mirza","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025051308430031600_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"2025051308430031600_bib13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"2025051308430031600_bib14","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat Commun"},{"key":"2025051308430031600_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.annonc.2022.11.003","article-title":"Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1\/ENGOT-ov25 trial subgroup exploratory analysis","volume":"34","author":"Labidi-Galy","year":"2023","journal-title":"Ann Oncol"},{"key":"2025051308430031600_bib16","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025051308430031600_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025051308430031600_bib18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-019-03917-z","article-title":"A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1\/ENGOT-OV24","volume":"84","author":"Mirza","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025051308430031600_bib19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of clinical genome resource (ClinGen), cancer genomics consortium (CGC), and variant interpretation for cancer consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med"},{"key":"2025051308430031600_bib20","doi-asserted-by":"crossref","first-page":"W420","DOI":"10.1093\/nar\/gkac373","article-title":"IBS 2.0: an upgraded illustrator for the visualization of biological sequences","volume":"50","author":"Xie","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2025051308430031600_bib21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat Cancer"},{"key":"2025051308430031600_bib22","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1016\/j.csbj.2021.08.007","article-title":"Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome","volume":"19","author":"Dong","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"2025051308430031600_bib23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/0008-5472.CAN-17-1494","article-title":"Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer","volume":"78","author":"Carey","year":"2018","journal-title":"Cancer Res"},{"key":"2025051308430031600_bib24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/cancers12030532","article-title":"Role of akt activation in PARP inhibitor resistance in cancer","volume":"12","author":"Gallyas","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025051308430031600_bib25","doi-asserted-by":"crossref","first-page":"8325","DOI":"10.1038\/ncomms9325","article-title":"LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair","volume":"6","author":"Liu","year":"2015","journal-title":"Nat Commun"},{"key":"2025051308430031600_bib26","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1126\/science.1139476","article-title":"Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response","volume":"316","author":"Wang","year":"2007","journal-title":"Science"},{"key":"2025051308430031600_bib27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s12885-019-5622-4","article-title":"Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes","volume":"19","author":"Da Costa","year":"2019","journal-title":"BMC Cancer"},{"key":"2025051308430031600_bib28","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1038\/s41467-021-27291-8","article-title":"Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma","volume":"12","author":"Zoumpoulidou","year":"2021","journal-title":"Nat Commun"},{"key":"2025051308430031600_bib29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12885-017-3639-0","article-title":"Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors","volume":"17","author":"Philip","year":"2017","journal-title":"BMC Cancer"},{"key":"2025051308430031600_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-14-179","article-title":"Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells","volume":"14","author":"Miyasaka","year":"2014","journal-title":"BMC Cancer"},{"key":"2025051308430031600_bib31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol Med"},{"key":"2025051308430031600_bib32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"2025051308430031600_bib33","doi-asserted-by":"crossref","first-page":"10892","DOI":"10.3390\/ijms231810892","article-title":"Sequential targeting of PLK1 and PARP1 reverses the resistance to PARP inhibitors and enhances platin-based chemotherapy in BRCA-deficient high-grade serous ovarian cancer with KRAS amplification","volume":"23","author":"Gasimli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025051308430031600_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","article-title":"Predicting splicing from primary sequence with deep learning","volume":"176","author":"Jaganathan","year":"2019","journal-title":"Cell"},{"key":"2025051308430031600_bib35","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","article-title":"The BRCA1-\u039411q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Res"},{"key":"2025051308430031600_bib36","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/ijgc-2022-004211","article-title":"Homologous recombination deficiency in newly diagnosed FIGO stage III\/IV high-grade epithelial ovarian cancer: a multi-national observational study","volume":"33","author":"Morgan","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"2025051308430031600_bib37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-023-01864-1","article-title":"Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid","volume":"22","author":"Roussel-Simonin","year":"2023","journal-title":"Mol Cancer"},{"key":"2025051308430031600_bib38","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1200\/JCO.2024.42.16_suppl.5547","article-title":"Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer","volume":"42","author":"Werner","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025051308430031600_bib39","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2217\/fon-2023-0167","article-title":"NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer","volume":"19","author":"Sghaier","year":"2023","journal-title":"Future Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0294\/3522620\/crc-24-0294.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/12\/3190\/3528217\/crc-24-0294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/12\/3190\/3528217\/crc-24-0294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:43:56Z","timestamp":1747125836000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/12\/3190\/750730\/Beyond-HRD-Status-Unraveling-Genetic-Variants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0294","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.28093838","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050122","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28093847","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28093835","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28093841","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28093850","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28093844","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28093832","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28093853","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727768","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727774","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050125","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7600241","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}